These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 2015173)

  • 1. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.
    Herchuelz A; Gangji D; Derenne F; Jeanniot JP; Douchamps J
    Br J Clin Pharmacol; 1991 Jan; 31(1):73-6. PubMed ID: 2015173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.
    Lennard MS
    Pharmacol Toxicol; 1990 Oct; 67(4):273-83. PubMed ID: 2077517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA; Harmer D; Downham DY; Whibley EJ; Idle JR; Ritchie J; Smith RL
    J Med Genet; 1983 Oct; 20(5):321-9. PubMed ID: 6644761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
    Sindrup SH; Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF
    Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Eur J Clin Pharmacol; 1997; 51(5):389-93. PubMed ID: 9049580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers.
    Graf T; Broly F; Hoffmann F; Probst M; Meyer UA; Howald H
    Eur J Clin Pharmacol; 1992; 43(4):399-403. PubMed ID: 1451720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
    Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis.
    Christensen PM; Gøtzsche PC; Brøsen K
    Pharmacogenetics; 1998 Dec; 8(6):473-9. PubMed ID: 9918130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive oxidative metabolism of dextromethorphan in patients with almitrine neuropathy.
    Belec L; Larrey D; De Cremoux H; Tinel M; Louarn F; Pessayre D; Gherardi R
    Br J Clin Pharmacol; 1989 Mar; 27(3):387-90. PubMed ID: 2719897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic oxidation of debrisoquine and sparteine.
    Eichelbaum M
    Prog Clin Biol Res; 1986; 214():157-67. PubMed ID: 3523506
    [No Abstract]   [Full Text] [Related]  

  • 20. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.